This page is for healthcare professionals only.
A Galapagos product may be discussed at these events.
Find the abbreviated SmPC here.
This page is not affiliated with ECCO.
This symposium is funded and organised by Galapagos.

Galapagos @ ECCO'24

Galapagos is proud to be a sponsor of the 19^th Congress of ECCO, taking place in Stockholm during 21-24 February 2024.

The ECCO'24 scientific programme features a range of sessions presented by some of the world's leading specialists in IBD, exploring highlights from recently published guidelines, clinical practice and important new data.

Join us and the expert faculty for this symposium, which will explore patient and physician perspectives on current treatment goals in ulcerative colitis (UC) and discuss how recent data can help us manage patients in clinical practice to meet these goals. Don't miss the faculty as they take turns in the hot seat, answering questions on the future of care for patients with UC!

SYMPOSIUM

STAY UP TO DATE

ABSTRACTS

Satellite
symposium

Date: Thursday 22 February 2024
Time: 11:00-12:00 CET
Location: Room A10

00

Days

00

Hours

00

Minutes

00

Seconds

19th Congress of ECCO 21-24 February 2024

Join Professor Tanja Kühbacher, Professor Flavio Caprioli, Professor Marte Lie Høivik and Salvatore Leone for the Galapagos-sponsored satellite symposium at ECCO'24.

Join us to:

Hear how patient and physician perspectives on current UC treatment goals can differ, and explore how aiming for optimal treatment goals can lead to significant improvements in patients’ lives
Explore recent clinical trial and early real-world data that demonstrate the variety of benefits that filgotinib, in the context of an established treatment landscape, can bring to patients with UC
Discuss how we can aim to achieve more for individual patients with UC
See our faculty in the hot seat as they consider topical questions in the management of UC

Have your chance to guide the discussion
Join our internationally renowned panel as they discuss these topics and share their experiences from the clinic. You will also have the chance to guide the discussion during our live Q&A session. Plus, be sure to catch our experts taking turns in the hot seat! They'll be answering quick-fire, highly topical questions that clinicians face every day in their practice.

REGISTER FOR UPDATES

AGENDA

Faculty

No Teaser Found

Abstracts^*

Posters and presentations will be made available as soon as they are presented at ECCO'24 (please see individual presentation times below).

Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

^{Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Jr, Ian Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Tomasz Masior, Christine Rudolph, Laurent Peyrin-Biroulet}

^{Session name: Guided Poster Session

Poster number: P678}

^{Session date: Friday, February 23, 2024

Session time: 12:40 - 13:40

Session hall: Poster Exhibition, Hall A}

GO TO POSTER

Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial

^{Stefan Schreiber, Brian G Feagan, Séverine Vermeire, Silvio Danese, Veerle Vyncke, Margaux Faes, Alessandra Oortwijn, Laurent Peyrin-Biroulet}

^{Session name: Guided Poster Session

Poster number: P772}

^{Session date: Friday, February 23, 2024

Session time: 12:40 - 13:40

Session hall: Poster Exhibition, Hall A}

GO TO POSTER

Mucosal transcriptomic profile associated with clinical response in patients with Ulcerative Colitis receiving filgotinib

^{Fernando Magro, Brian G Feagan, Gerhard Rogler, Laurent Peyrin-Biroulet, Yasmina Bauer, Laure Cougnaud, Alessandra Oortwijn, Matthew Randall, Christine Rudolph, Walter Reinisch}

^{Session name: Guided Poster Session

Poster number: P225}

^{Session date: Friday, February 23, 2024

Session time: 12:40 - 13:40

Session hall: Poster Exhibition, Hall A}

GO TO POSTER

^{*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease.

Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).}

Posters and presentations will be made available as soon as they are presented at ECCO'24 (please see individual presentation times below).

Correlation between patient-reported outcome measures in inflammatory bowel disease and other measures of disease activity: a systematic review

^{Xavier Calvet, Maria Giovanna Ferrario, Vanessa Marfil Vives, Santos Armenteros, Manuel Barreiro-de Acosta}

^{Session name: Guided Poster Session

Poster number: P368}

^{Session date: Friday, February 23, 2024

Session time: 12:40 - 13:40

Session hall: Poster Exhibition, Hall A}

GO TO POSTER

Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study

^{Javier P Gisbert, Stefan Schreiber, Corey A Siegel, Fernando Magro, Anna Jus, Chiara Whichello, Christine Michaels-Igbokwe, Sebastian Heidenreich, Alessandra Oortwijn, Séverine Vermeire}

^{Session name: Guided Poster Session

Poster number: P551}

^{Session date: Friday, February 23, 2024

Session time: 12:40 - 13:40

Session hall: Poster Exhibition, Hall A}

GO TO POSTER

^{*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease.

Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).}

News and views

Stay up to date!

I would like to receive informational and promotional communication via e-mail concerning Galapagos' products and services.

Select Salutation *

This field is required

First name *

This field is required

Regex pattern not matched.

You must maintain minimum length.

You must maintain maximum length.

Value did not matched with each other.

Last Name *

This field is required

Regex pattern not matched.

You must maintain minimum length.

You must maintain maximum length.

Value did not matched with each other.

Email address *

This field is required

Regex pattern not matched.

You must maintain minimum length.

You must maintain maximum length.

Value did not matched with each other.

Contact Telephone Number

This field is required

Regex pattern not matched.

You must maintain minimum length.

The number is too long

Value did not matched with each other.

Select Specialty *

This field is required

Main Place of Work *

This field is required

Regex pattern not matched.

You must maintain minimum length.

You must maintain maximum length.

Value did not matched with each other.

Related events

See all our events

VISIT MAIN EVENTS PAGE